The purpose of this study was to evaluate the safety and efficacy of percutaneous iodine-125 (125I) seed implantation using computed tomography (CT) or ultrasound guidance in the treatment of recurrent soft tissue mali gnanc1es after surgery and radiotherapy.From February 2002 to September.2009, 18.patients with 125recurrent sort tissue sarcomas were treated under ultrasound or CT guidance.The actuarial median number of(125 I) seeds implanted was 35 (range, 6-129), and the actuarial D90 of the implanted 125I seeds ranged from 107.9 to 204.4 Gy(median, 147.1 Gy).The activity of the seeds ranged from 0.4 to 0.8mCi (median, 0.7mCi).Follow-up times ranged from 4 to 78 months (median, 20 months).The median local control was 41 months (95% CI, 15.9-66.1months).The 1-, 2-, 3-, 4-, and 5-year local controls were 78.8%, 78.8%, 78.8%, 26.3%, and 0%, respectively.The median survival was 32 months (95% CI, 16-48 months).The actuarial 1-, 2-, 3-, 4-, and 5-year survivals were76.6%, 61.3%, 39.4%, 39.4%, and 39.4%, respectively.Seven (7) patients (38.9%) experienced recurrence after seed implantation.Six (6) patients (33.3%) died of distant metastases and 1 died of stroke.Two (2) patients developedulceration, 1 case caused by recurrence and another by a reaction of the skin to radiation.Percutaneous125I seed implantation for recurrent soft tissue malignancies under CT or ultrasound guidance is safe and is associated with high efficacy and low morbidity.